Download fulltext HTML
Satrio, J. (2022). Technology Transfer of COVID-19 Vaccines: Opportunities and Challenges. KnE Social Sciences, 7(12), 132–138. https://doi.org/10.18502/kss.v7i12.11513

https://doi.org/10.18502/kss.v7i12.11513

statistics

  • 393 Abstract Views
  • 161 PDF Views
  • 0 HTML Views

authors

  • Jati Satrio

    Jati Satrio

    Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia

Published Date

  • Aug 1, 2022

Technology Transfer of COVID-19 Vaccines: Opportunities and Challenges

KnE Social Sciences / 2nd Virtual Conference on Social Science In Law, Political Issue and Economic Development / Pages 132–138

Abstract

A solution to the ongoing global COVID-19 pandemic is the mass production of vaccines. Safe and effective vaccine development is one avenue to combat the ongoing pandemic. However, although the WHO has approved several vaccines for emergency use, developing and least-developed countries are still in an unfavorable position as they cannot secure those vaccines. Technology transfer initiatives are one solution to speed up the production process. Nevertheless, this proposal is still a work in progress. Despite the willingness of developing and least developed countries to manufacture the vaccine, several challenges, such as infrastructure and intellectual property rights, are hindering the technology transfer process.


Keywords: technology transfer, COVID-19, vaccine development, vaccine inequality

References
[1] E. Autio and T. Laamanen, “Measurement and evaluation of technology transfer: review of technology transfer mechanisms and indicators,” International Journal of Technology Management, vol. 10, no. 7–8, pp. 643–664, Jan. 1995, doi: 10.1504/IJTM.1995.025647.

[2] S. Derakhshani, “Factors Affecting Success in International Transfers of Technology,” The Developing Economies, vol. 22, no. 1, pp. 27–47, Mar. 1984, doi: 10.1111/j.1746- 1049.1984.tb00650.x.

[3] K. Putranto, D. Stewart, and G. Moore, “International technology transfer and distribution of technology capabilities: the case of railway development in Indonesia,” Technology in Society, vol. 25, no. 1, pp. 43–53, Jan. 2003, doi: 10.1016/S0160-791X(02)00035-0.

[4] G. Grohmann, D. P. Francis, J. Sokhey, and J. Robertson, “Challenges and successes for the grantees and the Technical Advisory Group of WHO’s influenza vaccine technology transfer initiative,” Vaccine, vol. 34, no. 45, pp. 5420–5424, Oct. 2016, doi: 10.1016/j.vaccine.2016.07.047.

[5] R. Dhere et al., “A pandemic influenza vaccine in India: From strain to sale within 12 months,” Vaccine, vol. 29, pp. A16–A21, Jul. 2011, doi: 10.1016/j.vaccine.2011.04.119.

[6] P. Pitisuttithum and P. Wirachwong, “A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand,” null, vol. 15, no. 10, pp. 2440–2445, Oct. 2019, doi: 10.1080/21645515.2019.1638205.

[7] A. E. Yeremia and K. H. Raditio, “Minding the Grassroots: Celebrating 70 Years of Sino-Indonesia Relations amid the Coronavirus Pandemic,” ISEAS Publishing, Indonesia, 2021, pp. 12–17. doi: 10.1355/9789814951159-007.

[8] K. Sharun and K. Dhama, “India’s role in COVID-19 vaccine diplomacy,” Journal of Travel Medicine, vol. 28, no. 7, 1-4, Oct. 2021, doi: 10.1093/jtm/taab064.

[9] I. Torjesen, “Covid-19 will become endemic but with decreased potency over time, scientists believe,” BMJ, vol. 372, p. n494,1-2, Feb. 2021, doi: 10.1136/bmj.n494.

[10] A. Hogan et al., “Report 33: Modelling the allocation and impact of a COVID-19 vaccine,” Imperial College London, London, Sep. 2020. doi: 10.25561/82822.

[11] M. Tatar, J. M. Shoorekchali, M. R. Faraji, and F. A. Wilson, “International COVID-19 vaccine inequality amid the pandemic: Perpetuating a global crisis?,” J Glob Health, vol. 11, pp. 03086–03086, Jul. 2021, doi: 10.7189/jogh.11.03086.

[12] A. Otu, E. Osifo-Dawodu, P. Atuhebwe, E. Agogo, and B. Ebenso, “Beyond vaccine hesitancy: time for Africa to expand vaccine manufacturing capacity amidst growing COVID-19 vaccine nationalism,” Lancet Microbe, vol. 2, no. 8, pp. e347–e348, Aug. 2021, doi: 10.1016/S2666-5247(21)00126-9.

[13] Chulalongkorn University, “The Latest Development in ChulaCov19 Vaccine,” Chulalongkorn University, Feb. 18, 2021. https://www.chula.ac.th/en/news/44920/ (accessed Nov. 24, 2021).

[14] A. Asundi, C. O’Leary, and N. Bhadelia, “Global COVID-19 vaccine inequity: The scope, the impact, and the challenges,” Cell Host & Microbe, vol. 29, no. 7, pp. 1036–1039, Jul. 2021, doi: 10.1016/j.chom.2021.06.007.

[15] P. Erfani, A. Binagwaho, M. J. Jalloh, M. Yunus, P. Farmer, and V. Kerry, “Intellectual property waiver for covid-19 vaccines will advance global health equity,” BMJ, vol. 374, p. n1837:1-4, Aug. 2021, doi: 10.1136/bmj.n1837.